Ownership

James B. Tananbaum

Insider Reports History

Entity: Individual
Location: 3052 Pacific Avenue, San Francisco, CA
Signature: /s/ James B. Tananbaum
All insider transactions: Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by James B. Tananbaum:

Stock	Role	Class	Num Shares	Value	Price $	Report Date	Ownership
ALUMIS INC.	Director, 10%+ Owner	Common Stock	4.2M	$67.2M	$16.00	Jul 1, 2024	Indirect
Gemini Therapeutics, Inc. /DE	Director, 10%+ Owner	Common Stock	412K	$27.8M	$67.65	Oct 4, 2021	Indirect
Quantum-Si Inc	Director	Class A Common Stock	4.46M	$7.9M	$1.77	Jun 10, 2021	Foresite Capital Fund IV, L.P.
Quantum-Si Inc	Director	Class A Common Stock	2.34M	$4.15M	$1.77	Jun 10, 2021	Foresite Capital Fund V, L.P.
Quantum-Si Inc	Director	Class A Common Stock	1.6M	$2.83M	$1.77	Jun 10, 2021	By Foresite Capital Opportunity Fund V, L.P.
Quantum-Si Inc	Director	Class A Common Stock	20.5K	$36.3K	$1.77	Jun 11, 2021	Direct
PARDES BIOSCIENCES, INC.	President and CEO, Director, 10%+ Owner	Common Stock	1K	$1.5K	$1.50	Aug 31, 2023	Indirect
Kinnate Biopharma Inc.	Director, 10%+ Owner	Common Stock	0	$0	$2.59	Apr 3, 2024	By Fund
Gemini Therapeutics, Inc. /DE	Director, 10%+ Owner	Stock Option (Right to Buy)	17.2K			Oct 4, 2021	Direct
ALUMIS INC.	Director, 10%+ Owner	Series A Redeemable Convertible Preferred Stock	0			Jul 1, 2024	Indirect
ALUMIS INC.	Director, 10%+ Owner	Series B-1 Redeemable Convertible Preferred Stock	0			Jul 1, 2024	Indirect
ALUMIS INC.	Director, 10%+ Owner	Series B-2 Redeemable Convertible Preferred Stock	0			Jul 1, 2024	Indirect
ALUMIS INC.	Director, 10%+ Owner	Series C Redeemable Convertible Preferred Stock	0			Jul 1, 2024	Indirect
ALUMIS INC.	Director, 10%+ Owner	Series Seed Redeemable Convertible Preferred Stock	0			Jul 1, 2024	Indirect
Kinnate Biopharma Inc.	Director, 10%+ Owner	Stock Option (right to buy)	0			Apr 3, 2024	Direct
PARDES BIOSCIENCES, INC.	President and CEO, Director, 10%+ Owner	Stock Option (Right to Buy)	0			Aug 31, 2023	Direct

Showing 1 to 16 of 16 entries

Insider Reports Filed by James B. Tananbaum

Symbol	Company	Period	Transactions	Value $	Form Type	Date Filed	Role
ALMS	ALUMIS INC.	Jul 1, 2024	32	$40M	4	Jul 3, 2024	Director, 10%+ Owner
ALMS	ALUMIS INC.	Jun 27, 2024	0	$0	3	Jun 27, 2024	Director, 10%+ Owner
KNTE	Kinnate Biopharma Inc.	Apr 3, 2024	5	$0	4	Apr 5, 2024	Director, 10%+ Owner
PRDS	PARDES BIOSCIENCES, INC.	Aug 31, 2023	5	$0	4	Aug 31, 2023	President and CEO, Director, 10%+ Owner
PRDS	PARDES BIOSCIENCES, INC.	Jun 1, 2023	1	$0	4	Jun 2, 2023	Director, 10%+ Owner
KNTE	Kinnate Biopharma Inc.	May 8, 2023	2	$4.98M	4	May 10, 2023	Director, 10%+ Owner
KNTE	Kinnate Biopharma Inc.	Feb 17, 2023	1	$0	4	Feb 22, 2023	Director, 10%+ Owner
KNTE	Kinnate Biopharma Inc.	Jun 13, 2022	1	$0	4	Jun 15, 2022	Director
PRDS	PARDES BIOSCIENCES, INC.	Jun 8, 2022	1	$0	4	Jun 10, 2022	Director, 10%+ Owner
PRDS	PARDES BIOSCIENCES, INC.	Dec 23, 2021	1	$0	4/A	Jun 10, 2022	Director, 10%+ Owner
PRDS	PARDES BIOSCIENCES, INC.	Dec 23, 2021	2	$0	4/A	Dec 30, 2021	Director, 10%+ Owner
PRDS	PARDES BIOSCIENCES, INC.	Dec 22, 2021	1	$3.25M	4	Dec 23, 2021	Director, 10%+ Owner
IRON	Gemini Therapeutics, Inc. /DE	Oct 4, 2021	1	$0	4	Oct 6, 2021	Director, 10%+ Owner
QSI	Quantum-Si Inc	Jun 10, 2021	7	$25M	4	Jun 14, 2021	Director
QSI	Quantum-Si Inc	Jun 10, 2021	0	$0	3	Jun 14, 2021	Director